15 & 16 FEBRUARY 2012 - GRANDE HALLE DE LA VILLETTE - PARIS - FRANCE
Pharmapack | An international exhibition and conference

Conference - Programme day 2 - Tuesday 2 February 2010


Download the conference
program in PDF :
Day 1  |  Day 2

 

 

8:30 OPENING OF THE EXHIBITION, EARLY MORNING COFFEE
9.00 11.30
Ma1
PACKAGING, COMPLIANCE AND PATIENT SAFETY

Chairpersons and opening of the session:
Professeur Philippe Arnaud, Pharmacien des hôpitaux - Chef de service, Hopital Bichat-Claude Bernard AP-HP, Paris
Sébastien Fily, Packaging development manager, Bayer Santé Familiale, France

Ma1.1

The role of packaging in improving patient compliance
Sandra Luciano, Global Product manager, Alcan Packaging, USA
Scott Denley, Global Product Manager, Alcan Packaging Flexible, Switzerland


1. What is patient compliance?
2. Benefits of patient compliance
3. Examples of patient compliance packs
4. International patient compliance perspectives

Ma1.2

New barrier materials for pharmaceutical tubes
Andreas Geiger, Head of Innovation/R&D, Neopac, Switzerland

 

After several years of work, Neopac has succeeded in developing unique materials that have never as yet been used to make flexible tubes for the pharmaceutical industry. Thanks to these materials, which naturally have all the certificates required by the pharmaceutical industry, our tubes offer excellent compatibility for products which, to date, had no suitable primary packaging. Furthermore, our clients will [To read more]

Ma1.3

Closures in child-resistant packaging : Past, Present and Future
Derek Hindle, Global Innovation Director, Global Closure Systems, France
Louis Meyerowitz, Vice President, United Closures and Plastics Limited, UK

 

There is no such item as a child-resistant cap, it’s the full pack that must be child-resistant

 

- A brief history of UCP introducing closures for child-resistant packaging into the UK
- The changing test protocol "Child-resistant / Elderly friendly"
- The challenges of getting packs to pass ISO8317-2003
- Mechanical testing to prove consistency & reduce protocol testing

Ma1.4

The first patented sterile distribution system
Isabelle Orhan, Directrice Innovation, Marketing, Développement, Promens, France
Vincent Cazelles, Director of Packaging Development, Laboratoires Pierre Fabre Dermo-Cosmétique, France

 

After eight years' research, Promens has developed the first patented sterile distribution system in partnership with Avène, a dermo-cosmetics pharmaceutical company (Pierre Fabre group).

 

Avène has created a real event by launching the first dermo-cosmetics equipped with the D.E.F.I. System : Tolérance Extrême is the only range that can truly claim to be preservative, perfume and surfactant-free. [To read more]

Ma1.5

Airless Dispensing Systems – an innovative approach in the delivery of semi-solid drugs
Karlheinz Klein, Sales Manager, MegaPlast GmbH & Co. KG, Germany

 

• An innovative approach in the delivery of semi-solid drugs
Demand for semi-solid drug formulations for use in topical or transdermal application of drug products continues to increase, driving the need for more innovative Dispensing Devices.

• Positive contribution to Patient compliance
Airless Dispensing Systems combine all features of a modern [To read more]

Coffee break, visit the exhibition

 

Ma1.6

Intelligent packaging solutions in patient compliance monitoring
Sari Häkli, Sales Manager, Stora Enso Carton Board, Finland

 

As patient non-compliance with medication is a universal problem, it is vital to make taking the right medication at the right time as easy as possible. Stora Enso Pharma DDSi is a ground-breaking packaging solution equipped with intelligence to enable the monitoring of patient compliance. This intelligent packaging solution, Stora Enso Pharma DDSi, provides exact data on the patient adherence and persistence [To read more]

Ma1.7

Pediatric packaging : how to involve the child in compliance
Jean-Marc Aiache, Professeur Emerite à la Faculté de Pharmacie de Clermont- Ferrand
François Jegou, Consultant in strategic design, Solutioning, Belgium / Designer professionnel et enseignant en design industriel à La Cambre, Bruxelles

 

After repeated accidents involving children, it is necessary to define to what extent the drugs and their packaging can be incriminated and how the situation can be remedied. Mix-ups between adult and pediatric doses, poor management of treatment by two households in the case of separated families, scattering of drugs around the various rooms in the home, drugs left within reach of young children, [To read more]

Ma1.8
The role of AFSSAPS in the monitoring and prevention of drug-related risks
Docteur Anne Castot, Chef du Service de l'évaluation, de la surveillance du risque et de l'information sur le médicament, AFSSAPS, Paris
12.00 12.30    Pharmapack Awards Ceremony

 

Lunch, visit the exhibition

 

2.00 4.30
Ma2
PACKAGING AND DELIVERY: PULMONARY, NASAL AND OPHTHALMIC FORMS

Chairpersons and opening of the session:

Jean-Marc AIACHE, Emeritus Professor, Faculty of Pharmacy, Clermont-Ferrand, France
Dr. Michael Spallek, Director of Packaging Development, Boehringer Ingelheim Pharma, Germany

Ma2.1
Current & future requirements for Pharma Polymers
Dr. Michael Spallek, Director of Packaging Development, Boehringer Ingelheim Pharma, Germany
Ma2.2

A New active dry powder inhaler (DPI)
Jean-Marc AIACHE, Emeritus Professor, Faculty of Pharmacy, Clermont-Ferrand, France

 

The phase out of chlorofluorocarbon pressurized metered dose inhalers (pMDIs) opened the way to introduction of both hydrofluoroalkane pMDIs and a range of dry powder inhalers (DPI), each seeking to address the expanding local and systemic market for inhaled drug delivery. Both platforms require patients to complete a number of movements (some of which must be co-ordinated) and inspiratory manoeuvres, [To read more]

Ma2.3

Think lateral: Development of an innovative side actuated nasal spray device
Hervé Pacaud, Director of Business Development, Valois Pharma, France

 

In the early 1970s the first nasal spray pump delivering a metered dose was introduced to the pharmaceutical market.

 

With time nasal drug products got more and more efficient: once a day dose regimens, lower doses limiting side effects, test masking drug formulations improving patient acceptance etc...

 

Drug delivery devices are also an important contributor to [To read more]

Ma2.4

Preservative free in drug delivery systems
Patrice Lewko, Global Marketing Director, Rexam Healthcare, France

 

Preservatives have been linked to side effects and allergic reactions. Their use especiallly in chronic treatments should be avoided wherever possible. This is especially true in for ophthalmic therapies due to the sensitivity of the eye. However in order to maintain convenience for patients and thus compliance, it has been a challenge to create ergonomic multidose devices: they need to be easy-to-use, safe from contamination and [To read more]

Ma2.5

Devices for intranasal vaccination
Degenhard Marx, DVM, Business Development Manager Pharma Division, ING. ERICH PFEIFFER GMBH, Germany

 

In the past, the intramuscular and oral administrations of vaccines were considered the ultimate ways of vaccination. Research triggered the development of intranasal vaccines, because it better resembles the natural way of infections and therefore may gain a reasonable share within the next couple of years. Another important advantage is that intranasal drop or spray administration is not invasive and causes little [To read more]

Ma2.6

Advanced Pharmaceutical Products Call for Intelligent Sorbents
Adrian Possumato, Global Director, Healthcare Packaging with Multisorb Technologies, Inc., USA

 

Dropping a sorbent into pharmaceutical packaging is a traditional and time-honored method for preventing product damage from moisture while maintaining shelf life and drug product efficacy. However, new and complex pharmaceutical formulations and packaging configurations, coupled with the ever-present pressures to speed new drugs to market, are requiring that sorbents become intelligent. [To read more]

Back to the top

 

Conference Registration - Options and fees
Pre-registration (before January 1st) VAT excl. VAT VAT incl.
1 day (euros)
280 €
55 €
335 €
2 days (euros)
440 €
87 €
527 €

 

After January 1st and on site VAT excl. VAT VAT incl.
1 day (euros)
350 €
69 €
419 €
2 days (euros)
550 €
108 €
658 €

 

Conference registration includes admission to all sessions on registered day(s); visitor admission to the exhibition hall, coffee breaks and luncheon each day; session materials for the day(s) you are registered and magazines and the exhibition guide.

 

Cancellation requests must be sent in writing before 15 January 2010. Past this deadline, registration fees shall not be reimbursed. However, substitutes may replace attendees upon request.

 

 

French